StockTipsArenaBeta

BUY Natco Pharma Ltd — Pradeep Haldar, PHD Capital

BUYNatco Pharma Ltd
Natco Pharma share price target & all analyst calls

byPradeep Haldar, PHD CapitalHorizon: 1–3 months12 Jun 2026via Business Today

Entry₹852.8Inferred
Target₹950
Total upside +11.40% (call closed)
Stop loss₹800-6.19% risk
Exit₹9501 Jul 2026, 12:07 pm
Target hit+11.40%0.00%upside left
Follow Pradeep Haldar for new calls(22% target hit, 32 closed calls)Get alertsWatch NATCOPHARM for new buy/sell callsGet alertsSee 1 active Short-term call on NATCOPHARMSee 43 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:38 pm IST
1 supporting1 neutral0 opposing
Supports the BUY call (1)

Natco Pharma Limited and Lupin Limited have received US FDA approval for Eribulin Mesylate Injection, a significant regulatory milestone.

BSE · Company Update·3 Jun · 4w ago

(opens in new tab)
Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Natco Pharma

All analyst calls on Natco Pharma

More from Pradeep Haldar, PHD Capital

Every call and its outcome